These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 28756882)

  • 1. Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC-a computational study.
    Bates AM; Lanzel EA; Qian F; Abbasi T; Vali S; Brogden KA
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2017 Aug; 124(2):157-164. PubMed ID: 28756882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.
    Brogden KA; Parashar D; Hallier AR; Braun T; Qian F; Rizvi NA; Bossler AD; Milhem MM; Chan TA; Abbasi T; Vali S
    BMC Cancer; 2018 Feb; 18(1):225. PubMed ID: 29486723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models.
    Lanzel EA; Paula Gomez Hernandez M; Bates AM; Treinen CN; Starman EE; Fischer CL; Parashar D; Guthmiller JM; Johnson GK; Abbasi T; Vali S; Brogden KA
    Cancer Immunol Immunother; 2016 Dec; 65(12):1511-1522. PubMed ID: 27688163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma.
    Malm IJ; Bruno TC; Fu J; Zeng Q; Taube JM; Westra W; Pardoll D; Drake CG; Kim YJ
    Head Neck; 2015 Aug; 37(8):1088-95. PubMed ID: 24710745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.
    Yearley JH; Gibson C; Yu N; Moon C; Murphy E; Juco J; Lunceford J; Cheng J; Chow LQM; Seiwert TY; Handa M; Tomassini JE; McClanahan T
    Clin Cancer Res; 2017 Jun; 23(12):3158-3167. PubMed ID: 28619999
    [No Abstract]   [Full Text] [Related]  

  • 8. miR-375 inhibits IFN-γ-induced programmed death 1 ligand 1 surface expression in head and neck squamous cell carcinoma cells by blocking JAK2/STAT1 signaling.
    Wu Q; Zhao Y; Sun Y; Yan X; Wang P
    Oncol Rep; 2018 Mar; 39(3):1461-1468. PubMed ID: 29328389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
    Yu D; Liu X; Han G; Liu Y; Zhao X; Wang D; Bian X; Gu T; Wen L
    Cell Commun Signal; 2019 Dec; 17(1):173. PubMed ID: 31881947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frameshift events predict anti-PD-1/L1 response in head and neck cancer.
    Hanna GJ; Lizotte P; Cavanaugh M; Kuo FC; Shivdasani P; Frieden A; Chau NG; Schoenfeld JD; Lorch JH; Uppaluri R; MacConaill LE; Haddad RI
    JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings.
    Boschert V; Teusch J; Aljasem A; Schmucker P; Klenk N; Straub A; Bittrich M; Seher A; Linz C; Müller-Richter UDA; Hartmann S
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinoma.
    Tsujikawa T; Ohno K; Morita KI; Saburi S; Mitsuda J; Yoshimura K; Kimura A; Morimoto H; Ogi H; Shibata S; Akashi T; Kurata M; Imoto I; Shimizu Y; Kano S; Watanabe A; Yamazaki T; Asada Y; Hayashi R; Saito Y; Ozawa H; Tsukahara K; Oridate N; Sano D; Horii A; Ueki Y; Maruo T; Mukoyama N; Hanai N; Fukusumi T; Iwai H; Fujisawa T; Fujii T; Nibu KI; Iwae S; Ueda T; Chikuie N; Yasumatsu R; Matsuo M; Umeno H; Ono T; Masuda M; Toh S; Itoh K; Hirano S; Asakage T
    Front Immunol; 2024; 15():1390873. PubMed ID: 39136017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma.
    Tran L; Allen CT; Xiao R; Moore E; Davis R; Park SJ; Spielbauer K; Van Waes C; Schmitt NC
    Cancer Immunol Res; 2017 Dec; 5(12):1141-1151. PubMed ID: 29097421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance.
    Chen SW; Li SH; Shi DB; Jiang WM; Song M; Yang AK; Li YD; Bei JX; Chen WK; Zhang Q
    Int J Biol Markers; 2019 Dec; 34(4):398-405. PubMed ID: 31674884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical applications of PD-L1 bioassays for cancer immunotherapy.
    Liu D; Wang S; Bindeman W
    J Hematol Oncol; 2017 May; 10(1):110. PubMed ID: 28514966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.
    Skinner HD; Giri U; Yang LP; Kumar M; Liu Y; Story MD; Pickering CR; Byers LA; Williams MD; Wang J; Shen L; Yoo SY; Fan YH; Molkentine DP; Beadle BM; Meyn RE; Myers JN; Heymach JV
    Clin Cancer Res; 2017 Jun; 23(11):2713-2722. PubMed ID: 28476872
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians.
    Outh-Gauer S; Alt M; Le Tourneau C; Augustin J; Broudin C; Gasne C; Denize T; Mirghani H; Fabre E; Ménard M; Scotte F; Tartour E; Badoual C
    Cancer Treat Rev; 2018 Apr; 65():54-64. PubMed ID: 29547766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches.
    Udager AM; Liu TY; Skala SL; Magers MJ; McDaniel AS; Spratt DE; Feng FY; Siddiqui J; Cao X; Fields KL; Morgan TM; Palapattu GS; Weizer AZ; Chinnaiyan AM; Alva A; Montgomery JS; Tomlins SA; Jiang H; Mehra R
    Ann Oncol; 2016 Sep; 27(9):1706-12. PubMed ID: 27217541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bioinformatics analysis of programmed cell death ligand 1 co-expression genes and their regulatory network in head and neck squamous cell carcinoma].
    Yang LS; Shi CY; Liang YH; Liu T; Hou XR; Tian XD; Wang XY
    Hua Xi Kou Qiang Yi Xue Za Zhi; 2019 Oct; 37(5):516-520. PubMed ID: 31721500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determining PD-L1 expression in head and neck squamous cell carcinoma using immunohistochemistry.
    Mishra PS; Sidhu A; Dwivedi G; Mulajker DS; Awasthi S
    Indian J Cancer; 2022; 59(4):474-479. PubMed ID: 33753620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.